Impact Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Impact Capital Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.02M	Sell	2,046 -117	-5%	-$51.9K	0.28%	92
2026 Q1	$966K	Sell	2,163 -63	-3%	-$29.4K	0.29%	77
2025 Q4	$1.01M	Buy	2,226 +75	+3%	+$32.3K	0.3%	71
2025 Q3	$842K	Buy	2,151 +12	+0.6%	+$5.01K	0.25%	81
2025 Q2	$952K	Sell	2,139 -337	-14%	-$155K	0.31%	72
2025 Q1	$1.2M	Buy	2,476 +232	+10%	+$108K	0.43%	60
2024 Q4	$904K	Buy	+2,244	New	+$1.04M	0.32%	77

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

GIA

Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return

IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Impact Capital Partners's VRTX Position: Q2 2026 in Review

Impact Capital Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 5.4% in Q2 2026, selling an estimated $51.9K and leaving 2,046 shares worth $1.02M. The position accounts for 0.28% of the portfolio, ranked #92.

Impact Capital Partners first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.2M in Q1 2025. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Impact Capital Partners held 2,046 shares of Vertex Pharmaceuticals worth $1.02M as of Q2 2026.
Impact Capital Partners sold 117 Vertex Pharmaceuticals shares in Q2 2026, an estimated $51.9K.
Vertex Pharmaceuticals made up 0.28% of Impact Capital Partners's portfolio in Q2 2026, its #92 holding.
Impact Capital Partners first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Impact Capital Partners's Vertex Pharmaceuticals position peaked at $1.2M in Q1 2025.
334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Impact Capital Partners's 13F filing for Q2 2026, filed 14 Jul 2026.